BioCentury
ARTICLE | Clinical News

AZ's MEDI0382 reduces glucose and body weight in Phase IIa for Type II diabetes

July 6, 2018 4:44 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said once-daily 200 µg subcutaneous MEDI0382 significantly reduced glucose area under the curve (AUC) from 0-4 hours after a Mixed Meal Tolerance Test (MMTT) (32.8% vs. 10.2%, p<0.0001) and body weight (3.8 vs. 1.7 kg, p=0.0008) from baseline to week six vs. placebo in a Phase IIa trial to treat Type II diabetes. Data were presented at the American Diabetes Association meeting in Orlando and published in The Lancet.

Among 51 Type II diabetics in the double-blind, German trial, MEDI0382 also significantly reduced HbA1c (0.9% vs. 0.6%, p=0.0004), fasting plasma glucose (FPG) (2.8 vs. 1.1 mmol/L, p<0.0001) and hepatic fat content (39.1% vs. 19.5%, p=0.0172) vs. placebo...